AstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor developed through an allian
Multimillion-dollar diabetes collaboration between two leading pharma players. A global collaboration has been formed on phase III-ready diabetes drug ertugliflozin between Pfizer and Merck.
